Much of Moderna’s focus is on nabbing FDA approval for a respiratory syncytial virus vaccine, a decision expected in a matter ...

Agricultural Activator Adjuvant Market set to hit worth US$ 6.6 billion at CAGR 4.9% during forecast period 2024 to 2034 ...

On 18 April 2024, the US Food and Drug Administration (FDA) approved Roche’s Alecensa (alectinib), an oral anaplastic ...

A djuvant radiotherapy (RT) after radical prostatectomy did not improve outcomes in prostate cancer as compared with salvage ...

The global agricultural adjuvant market is forecast to expand at 6% CAGR over the forecast period, as per FMI’s analysis. The ...

Roche has broken new ground with its ALK inhibitor Alecenesa, becoming the first drug in the class to be approved by the FDA ...

Highly anticipated overall survival results from the KEYNOTE-564 trial support the use of adjuvant pembrolizumab as a standard of care after nephrectomy for patients with clear cell RCC at increased ...

The US Food and Drug Administration (FDA) has approved alectinib (Alecensa, Genentech) in the adjuvant setting following ...

The FDA has approved Alecensa (alectinib) as adjuvant treatment for adults with ALK-positive non-small cell lung cancer.

Alectinib approved by US FDA for auxiliary treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small ...

The Food and Drug Administration (FDA) has approved Alecensa (alectinib) for adjuvant treatment in adults following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung ...